Evaluate Vantage Homepage
Proqr eyes its first big test
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
Biogen hints at jobs cuts unless government pays up
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
After a record year, where next for biopharma flotations?
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
Medtech
Device makers buy big
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
Company Events
Proqr eyes its first big test
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
Days of reckoning for immune checkpoint blockers
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
Interviews
Argenx’s independent streak approaches its biggest test
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Investors back Quell’s Treg approach
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
Global Blood takes on gene therapy
Proof-of-concept data at Ash should give clues about whether GBT021601 could be an oral functional cure for sickle cell disease.